Home / Transcripts / Alpha Cognition Inc. (ACOG) · November 11, 2026

Alpha Cognition Inc. (ACOG) Earnings Call Transcript

November 11, 2026

NASDAQ US Health Care Biotechnology earnings 44 min

Earnings Call Speaker Segments

Michael McFadden executive
#1

Thanks, Joe. Good afternoon, everyone, and I'm glad you could join us for Alpha Cognition's call on our financial results for the third quarter of 2026. We issued a press release with those results today after the market closed. With me today are Michael McFadden, Alpha Cognition's Chief Executive Officer, and Lauren DeAngelo, Chief Operating Officer. Today's call is accessible through the investor section of the company's website at www.alphacognition.com. On this call, management will make certain forward-looking statements regarding future events and the company's future performance; those forward-looking statements reflect Alpha Cognition's current perspective on existing trends and information. Statements of this forward-looking nature don't promise how we'll perform down the road; they carry risks and uncertainties, among them the ones described in the Risk Factor Section of the Commission's most recent SEC filings. What actually happens could differ substantially from what those forward-looking statements anticipate. So that those of you listening to the replay have the right context: this call is taking place and being recorded on November 11, 2026. After that date, the company might have issued further announcements about the subjects we're covering. Kindly consult the company's latest press releases and its current SEC filings. Except where applicable securities laws demand it, Alpha Cognition accepts no duty to revise these forward-looking statements.

Michael Freeman executive
#2

I'll hand things over to Michael now. Michael? Thanks, Henry. Good afternoon, everyone, and welcome to today's call. The third quarter of 2026 was the strongest quarter we've had since Zunville launched — the first new oral Alzheimer's treatment approved in over a decade. We saw accelerating demand along with record adoption by prescribers and facilities, while keeping operating spend basically flat versus the second quarter; that growth, combined with disciplined operating spend, is consistent with our objective of reaching operating profitability in 2027. On this call, we'll... stress four main points. Zunvale's growth is picking up speed. That growth came on better targeted calls. Tight cost control means we remain on course to reach operating profitability by 2027. We'll also put a focus on real-world data for Zunvale, since its market positioning and differentiation continue to strengthen. Net product revenues for Q3 landed at approximately 7.8 million, representing sequential growth of about 30% versus Q2 2026. Field prescriptions climbed roughly 31% from the prior quarter. Across six quarters of commercialization, Zunville has surpassed 30,000 prescriptions filled. We're pleased with the growth these numbers reflect, as HCP riders, cumulative riders since launch, and homes holding Zunvel prescriptions all matched or exceeded our expectations for the quarter. Lauren will soon provide further specifics regarding the KPIs and how our commercial efforts are advancing, though I’ll note that management feels good about where we stand on KPI achievement at this stage of the year. Turning to our clinical and medical programs, we continue to publish actual data from the environment in which these patients receive treatment. We think the evidence the company is producing will support us in conversations with long-term care clinicians and with payers. I’ll start with Converge. On October 1st, we reported initial findings from Converge, a retrospective real-world evidence initiative drawing on longitudinal long-term care data. There are two points I want to emphasize. The first concerned titration data. Of the residents either starting acetylcholinesterase inhibitor treatment for the first time or moving over from a rival product, roughly 80% of those on Zimbel were new to the inhibitor and got to a therapeutic dose inside 180 days; on this measure it beats every other drug in the class statistically. For thirty years, the class's largest real-world shortfall in nursing homes has been that patients never reach an effective dose, since they can't tolerate the older medicines. That makes me quite encouraged about what these figures suggest regarding Zunvel's capacity to change outcomes. Polypharmacy is the second point. At Zunville, residents typically stopped taking two categories of drugs, which caused an overall reduction across all eight drug categories we assessed—antipsychotics, other psychotropics, gastrointestinal drugs, and sleep drugs were among them. The reverse happened for residents on genetic generic acetylcholinesterase inhibitors: they added two additional drug categories and then discontinued, with overall increases across those same eight drug categories just mentioned. Given a context in which polypharmacy drives cost, staff burden, and CMS quality measures, we think these findings will connect with our nursing home providers, the nursing homes themselves and their staff, and with payers. Converge remains in progress, and we anticipate additional dataset updates in January and March, which should expand the number of Zunville residents available for analysis. We anticipate releasing Converge data starting in the first half of 2027. Turning to Beacon, 11 abstracts have been finished and presented at medical conferences. That analysis addressed cognition, activities of daily living, neuropsychiatric symptoms, tolerability, treatment patterns, and psychotropic medication utilization; medical professionals can now access the data on the Alpha website under the medical affairs tab. RESOLVE, our interventional trial in patients with behavioral symptoms, remains open for enrollment, and over 57 patients have enrolled so far. Our expectation remains that this study will wrap up in the second half of 2027, and top-line data will be shared once it concludes. Regarding development, work continues on our sublingual program. The pharmacokinetic study we ran wrapped up at the start of October, and what it produced did not give us a clear answer. Management thinks a further trial—set to kick off in the first days of January—can settle the question. CMS Pharma, our partner, will continue advancing the regulatory work across Asia, and we expect clearances in a pair of countries there before long. We answered the questions and inquiries the Chinese regulatory authorities raised about the program, and we're waiting to hear whether they have anything further to ask. On the intellectual property side, in October we announced that the US Patent and Trademark Office published our patent application covering proprietary manufacturing processes for benzgalantamine. Beyond that, during the quarter we secured approval of the Benz Galantamine Polymorph patent in Hong Kong and Russia. That gives Benz Galantamine stronger patent protection in the U.S. market and worldwide. The company expects more patent approvals in the weeks and quarters ahead. With that, I'll hand the call to Lauren to talk about our commercial progress. Lauren.

Lauren D'Angelo executive
#3

Thank you, Michael. This quarter was the strongest we've had since launch, with demand continuing to grow and a meaningful gain in commercial productivity. In Q3 we brought in net product sales of roughly 7.8 million dollars, which is 30% higher sequentially, powered by more than 11,000 filled prescriptions, a rise of about 1.5 million dollars in net product sales, and a rise of about 1.5 million dollars in net product sales. That works out to roughly 40% quarter over quarter. Net revenue per prescription stayed essentially flat at about $650 per bottle, which shows volume of prescriptions, not price, drove the growth. Just as important, we're getting more productive in how we create that demand. In Q3, our commercial team made 7,000 calls and connected with about 3,400 targeted prescribers; we keep sharpening both whom we call on and how often we engage, and that sharper focus is showing results. HCP writers rose 23% sequentially to 1,654, and cumulative writers hit 2,400. Over half of the prescribers we called on wrote Zunvale in Q3, versus roughly 35% in Q2. With 2,438 cumulative writers launched today, we've already beaten our original full-year goal of about 2,000 prescribers with one quarter left. remaining and remain on track to exceed our revised goal of 2500. Importantly, we aren't just adding writers. We're seeing more depth within the prescriber base we already have. About 78% of prescribers placed repeat prescriptions, while productivity climbed to roughly seven prescriptions per writer, up from about six in Q2. Momentum at the facility level looks similar. We called on about 2,800 nursing homes during the quarter, and homes with a Zunvale prescription grew 29% sequentially to 1,400, with about 80% of those homes placing repeat orders. Cumulatively, we've now reached 1900 ordering homes, with 81% placing repeat orders. Expansion carried on through quarter end, including 103 new ordering homes in September alone. We're pleased that a significant and growing share of our business now comes from the psychiatry channel, including psychiatrists, nurse practitioners, and physician assistants practicing in long-term care. On payer access, we keep seeing encouraging progress. Where our reimbursement team supports the prior authorization process, about 95% of prescriptions are approved, and about 70% percent of long-term care lives have access to Zunvale with a $0 copay. What's especially encouraging to us is that we delivered strong sequential prescription growth in Q3 without a meaningful change in formulary access. As broader contracted access rolls out downstream, we believe payer access can become another driver of growth. As Michael discussed, our real-world evidence program is also starting to support our commercial efforts in a very practical way. One of the questions our representatives hear most often since launch is whether frail, long-term care residents can successfully be titrated to an effective dose. The conversion real-world data, provide real-world evidence addressing that question, and give our commercial team additional evidence to support conversations with healthcare professionals. Looking at it overall, Q3 showed progress in the main areas we've been concentrating on: demand that is picking up speed, better commercial productivity, growth in and deeper development of our prescriber base, greater penetration of facilities, and headway on payer access. We beat our initial prescriber target for the full year by a quarter ahead of schedule and stay on track to surpass our home goal; with growing depth among current prescribers and facilities, ongoing customer expansion, and additional payer access still in front of us, we think Zunvale is heading into the fourth quarter from a position of rising commercial strength. I'll hand things over now to Henry, who will go through the financials in more detail.

Michael McFadden executive
#4

Thanks, Lauren. Hello again, everybody. During Q3 of 2026, Zonvale brought in around $7.8 million in net product revenues, versus roughly $6 million in Q2 — that works out to about 30% growth sequentially. Looking year over year, the comparison is $2.3 million of net product revenues in Q3 of 2025. That's growth above 230%. YAP growth product margin came in at about 94% for Q3, in line with the prior quarter. Total operating expenses in Q3 were $13.7 million, versus $12.9 million in Q2 and $5.6 million in Q3 of 2025. Within that, SG&A was roughly $12.4 million and R&D expense was $1.3 million. The point worth emphasizing is that our spend stayed relatively flat on a sequential basis while revenue climbed 30%; we posted an operating loss of $6.4 million for the quarter, better than Q2, and that's a direct result of revenue growth outpacing spend. The net loss in Q3 was $7.6 million, or 35 cents per share, versus a net loss of $8.2 million, or 38 cents per share, in Q2. The gap between our operating loss and our net loss comes from approximately $1.2 million of non-operating items, mainly a non-cash charge tied to the change in fair value of warrant liabilities. At September 30th, 2026, the company held $37.8 million in cash and cash equivalents, versus $41.4 million at June 30th, 2026. The company is still debt-free. Cash went down only about $3.6 million during the quarter, and that figure includes roughly $1.4 million of proceeds from warrant and stock option exercises. Sequentially, these numbers show both revenue growth and expense discipline. We're reiterating the full-year 2026 operating expense guidance we provided last quarter; through the first three quarters, we've spent approximately $37.5 million, which keeps us comfortably inside the $50 million-$54 million range for the full year. We aren't giving revenue guidance at this time. As we said last quarter, we expect to provide guidance for 2027 — expense guidance for 2027 — either late in Q4 or right at the start of 2027. I'll hand it back to Michael now for closing remarks. Thanks, Henry. Let me quickly summarize what I see as the key takeaways.

Michael Freeman executive
#5

Let me share the main points from this quarter. First, growth at Zumbel is speeding up. Second, we are delivering that growth through better targeted calls and operational efficiency. Third, we are showing operating leverage, and we are still on track for operating profitability in 2021. And fourth, the company continues to be excited about the real-world evidence we are building. This data is compelling and highly differentiating both for our customer base and for the payers; with that, operator, let's open the floor for questions.

Executive executive
#6

Hello everybody, congratulations on everything you’ve accomplished. Zunville appears to be performing very well. Given that, and the progress you’ve observed, I’d like to hear your thinking on whether you might expand Salesforce or the territories where you’ve promoted. What sales milestones, or which metrics, would you need to see internally before you’d consider broadening the promotional effort? Thank you.

Lauren D'Angelo executive
#7

Okay, so at this point we feel our existing commercial infrastructure is the right size for where the business stands today. As we move forward and grow, we'll keep assessing the capacity of our field force along with its productivity. And naturally, we'll put money in wherever we think we can earn an attractive return; but a couple of the key indicators we've discussed during earlier quarters, and which hold true right now, is first, formulary coverage. When we consider expanding beyond long-term care, we believe it's really important to have formulary coverage in place for those outpatient patients. And we're likewise focused on simply maximizing long-term care. So at present, we see a significant opportunity to maximize where we are. We think the broad adoption we currently have with our 2,500 riders is evidence of broad adoption. But there's a substantial opportunity for us to deepen and make more consistent prescribers before we would actually expand into either additional prescribers or move outside of long-term care.

Raghuram Selvaraju analyst
#8

Thank you for that question, and congratulations on this quarter's growth. Which main initiatives or dynamics would you say are behind the prescriber growth that beat expectations? And what accounts for the rise in prescriber conversion of 50% compared with what we saw in the second quarter? Also, how do you expect this to evolve going forward? I have a follow-up.

Lauren D'Angelo executive
#9

Sure. So it's quite similar to what we've described before regarding how quickly an Alzheimer's therapy gets adopted, particularly among long-term care providers; this is a frail patient population. They tend to adopt a bit more slowly than, say, the retail setting for an Alzheimer's therapy. So what we think is really driving the growth is experience. Physicians need to gain experience with the product. Patients need to be able to go through that access and fulfillment process with a new therapy. And then, of course, prescribing behavior builds over time. So when we look at our prescribers today and why we're seeing a significant increase, it really comes down to giving them time to gain experience with our drug. The drug is working. It's working far better than we thought it would; we're seeing a significant impact, not just on tolerability, but obviously on the behaviors associated with Alzheimer's disease. So as physicians gain experience, they write more; and you can see that in the metric where, last quarter, they wrote about six prescriptions. We've increased that to seven. They're simply getting more comfortable with the drug, and then they're adding it to additional patients. So we believe experience with Zunvale will keep contributing to that growth.

Raghuram Selvaraju analyst
#10

Thank you. Could you also give us a bit more detail on the inconclusive study for the sublinguals and no format, and tell us what other items still need to be completed before the IND submission there? Thanks.

Michael Freeman executive
#11

Yes. So we observed a signal in the PK data, specifically AUC, that did not line up with earlier data sets we had concluded. We've concluded four data sets involving both Zunvel, the DR tablet, which was part of this study, and the sublingual and intranasal products. The data did not match prior data we had seen. So our view is that it might be an analysis issue on the CRO side, or it might be a species issue with the species that was used in the study. We are therefore going to initiate an additional study in the first quarter of next year, and we think that will settle those issues and let the company move forward. Our belief is that this is the only study remaining to advance that product, along with a meeting with the agency, which would take us to the clinic. And we believe the, um,.

Raghuram Selvaraju analyst
#12

Thank you very much for taking our questions, and congratulations on everything that's been accomplished this quarter. First, I'd like to ask whether you can provide any further visibility on what recent formulary or contracting wins have come about since the second quarter, and what you expect might potentially be achievable on the access side between now and the end of this year. And looking toward 2027, what are the company's core objectives on that front as you aim to speed up market uptake for Zonvile?

Lauren D'Angelo executive
#13

Sure. Payer coverage has stayed unchanged since the earlier quarters. Obviously, we had hoped we would see some adoption. But we absolutely believe broader coverage can be achieved. What we're seeing, obviously, is that market access is a process, especially for a new product, and timing varies considerably from plan to plan. So what we're doing, our focus, is that we keep engaging payers, and we do believe our growing physician experience, the rise in volume, the patient utilization, and of course the accumulating real world experience and evidence we're generating will support those discussions. At this point, we don't expect any formulary wins in the next couple of months through the rest of the year, but we are very focused, as we always have been, on the specific plans we're engaging with, and we do hope to see some traction early next year.

Raghuram Selvaraju analyst
#14

And regarding repeat prescribers and productivity measured as prescriptions per prescriber, do you anticipate those statistics rising substantially over the next several quarters? Or is it your view that, for instance, given you're now in the high seventies on repeat prescribers, this has more or less settled into a steady state, and that growth will mainly be driven by expansion and access, by adding more facilities, and by growing the number of new-to-brand prescribers?

Lauren D'Angelo executive
#15

That's something we focus on every single day. We firmly believe there's a substantial opportunity to deepen and make more consistent the prescribing among existing writers. So while we obviously intend to keep adding new writers, and we add a significant number every single month, month, the bigger opportunity for us at present is really to build that depth and consistency. So we do expect repeat rates to rise across the board with our providers and our customers, and we're seeing that month by month and quarter by quarter. So it really is about expanding the writers, but even more importantly, going deeper with our existing writers is where our focus is today. Now, of course, formulary coverage, oh, sorry, go ahead. No, no, go ahead, please. Yes, so formulary coverage is, of course, incremental, uh, you know, upside for the company. We're very pleased with how much progress we've made and the the goals we've been able to hit with, you know, a lack of formulary coverage. So we actually see formulary coverage providing significant upside, uh, for the company.

Raghuram Selvaraju analyst
#16

Now, regarding the real-world evidence and phase four data that you already possess and that you anticipate generating soon — how do you think that will factor into the promotional messaging you're currently running, and what does your market research suggest the effect might be, especially the data showing how easily Zonvile residents get to therapeutic dose and how much patients on Zonvile are able to reduce use of certain concomitant medications?

Lauren D'Angelo executive
#17

What we've observed up to now is quite early. We clearly only just announced that data. So we're in fact still at work on that promotional messaging. But market research, you know, indicates those are key indicators. Among the biggest problems with this class is that most of these patients taking a generic acetylcholinesterase inhibitor cannot reach the therapeutic dose because of tolerability issues; that really was, you know, clearly the basis for launching Zunvale in the first place. So that message resonates strongly in market research with our customers, and so does the polypharmacy message. Those were the two most important factors, which is why we in fact released that data, and we obtained that data at the earliest point. Now, as we make progress on some of the other evidence we're generating, we're generating this data over time. You know, all of the information we're putting in front of our customers in terms of what we're examining is highly compelling from an adoption perspective. But I do want to emphasize that what we have today — our current story for Zunvale and the experience they are in fact getting with our drugs — is just as good. We're looking at all of this real-world data as upside incremental to what we already have and what we launched with from a promotional message perspective.

Michael Freeman executive
#18

And Ram, I’ll simply include every piece of polypharmacy data, dosing data, pharmacology data, and pharmacoeconomic data that we hold and that hasn’t been published but is still to come, along with further pharmacoeconomic analysis, which will be used with payers to strengthen those discussions and will go into the dossier, formularies, kits, and so on, with other decision makers across the stakeholder segment that we call on.

Raghuram Selvaraju analyst
#19

Could you give us a quick clarification on the process patent whose publication you announced? I think that was last month. Could you give us a sense of how much protection that is likely to provide? To what degree might it pose a meaningful and potentially unique hurdle that generic competitors would have to try to get past? And if it does get issued, what do you expect the potential expiration timeframe would be, without factoring in Hatch-Waxman extensions or patent term adjustments? Thank you.

Michael Freeman executive
#20

Let me take the last question first. That patent would give us protection through 2045 in the U.S. We think it comes on top of the other patents we hold that cover the product, which include Polymorph, a structural patent, Composition of Matter, method of use patents, and then we have some additional orange book patents that have been filed and accepted and approved by USPTO. So we're building a really nice patent shield around the product to protect it in all ways. The manufacturing product is really interesting in that the claims made provide protection on how the product is manufactured. So when you manufacture a prodrug, there are specific processes that one needs to use. We've identified those that are novel. It had unexpected findings that provided us that patent. So we believe it's protective of the product in addition.

Chase Knickerbocker analyst
#21

Good afternoon, and thank you for taking our questions. Apologies for the technical issues earlier. Congrats on a fantastic quarter. Perhaps, regarding formulary coverage while we wait for pull-through, I'm just trying to understand how often that friction point arises with the prior auth. Is there a revenue threshold you tend to see at an account where that friction begins because of the prior authorization? Perhaps a clearer way to frame the question is whether any of your high-volume accounts have reached points where volumes begin to flatten out, specifically because of friction related to prior authorization.

Lauren D'Angelo executive
#22

That hasn't happened for us so far. In our view, there remains a considerable opportunity with Zunvale when it comes to generating demand and increasing volume. In the past, there was a particular friction point at which that would occur, but we are definitely not at that stage yet. As we've discussed previously, our payer coverage is MedD, and four plans are the ones that matter. Obviously, we're pushing as much volume as we can across all four of those plans in order to place honest friction on the payer, so they'll keep engaging and clearly continue working with us on formulary coverage. But at this moment, we haven't reached a point where it's beginning to level off. What I'll say is that the prior authorizations are real. The great news is our team keeps getting better and better at supporting that prior authorization process. Whenever our team gets involved with a prior authorization, the approval rate comes out at 95%. So, as you might expect, the majority of our writers—particularly those handling high volume—are quite accustomed to it, at ease with it, and they understand how to navigate the prior authorization process. They collaborate with our team to ensure Zunvale secures approval through that process. I would love to provide a specific answer, but regrettably, we haven't yet reached the point of hitting a particular milestone.

Chase Knickerbocker analyst
#23

That's clear, I follow you. Perhaps a good way to lead into the next question. Right now, what share of your total demand do those prior auths represent that you're handling? And with a 95% success rate, how could you grow that further? Then secondly, in those accounts where you are handling that prior auth, do you see more scripts per writer?

Lauren D'Angelo executive
#24

Yes on both counts. Clearly, we are fully focused on raising the count of prior auths our team touches; that's our top priority. There are also other paths where the provider feels quite comfortable. They've got a system in place inside their own practice, inside their facility, allowing them to process those PAs. What we've managed is to become really efficient with our targeting. We concentrate heavily on those physicians willing to work with our team, and we concentrate heavily on those pharmacies willing to work with our team, so that our effort truly leads to a successful prior authorization approval. That's precisely what we're doing, and we keep seeing greater support from our team month after month, and you see it growing. Obviously, it also involves getting our representatives to pull through that process too. So yes, we're focused on increasing as many prescriptions as we can with our team. Now, giving you an exact number is pretty difficult, but in terms of what our team is touching, it is significant.

Chase Knickerbocker analyst
#25

Understood. And you've sort of got room there to handle, you know, even more?

Lauren D'Angelo executive
#26

Definitely. Our team has become incredibly efficient at processing these PAs. They are truly, truly skilled. And we're actually, you know, they're also collaborating with offices. At this point offices are actually, it's become quite good at handling the prior authorizations by themselves too. So it's a partnership involving us and our customers. And we're carrying on with that.

William Wood analyst
#27

Hello, and thank you for taking the questions, and congratulations on the quarter. So, just — since we're already a bit more than a month into the fourth quarter, could you give us some color on how you're seeing new patient enrollment and script growth through, you know, through the start of the quarter, and perhaps how that positions things as we head toward year end? What are your expectations for gross to net through the end of the year? And then, as we move into 2027, once PBM rebates into the two-part D contracts are paid, should we expect a change in gross to net, and maybe a change in price as well? And then I have a follow-up.

Lauren D'Angelo executive
#28

Okay, so I'll take that; we expect the GTN to remain roughly the same, as you know, as more patients get through the end of the year, with the IRA, you might see somewhat more patients come into what used to be called the donut hole; but, no, we do expect a fairly consistent GTN through the remaining Q4. We don't plan to take any, you know, price either. So our price will stay the same through the end of the quarter. Did I answer both of your questions? I know you had a three-part. Did I answer? Is there one more question in there? Yes, in 2027, should we expect a change in early 2027 and or price or gross to net and.

William Wood analyst
#29

So what are you seeing so far when it comes to scripts and new patient enrollment, considering we're roughly a month and a half, or a month, into the fourth quarter?

Lauren D'Angelo executive
#30

Sure, so our growth keeps going. I know we don't offer guidance on revenue or prescriptions, but growth is continuing as we move through the fourth quarter; that's really all I'll say about that. Then as we head into Q1 of next year, we don't expect — at this point, we haven't made any decisions regarding price, but we do expect the GTN, unless we see a formulary, obviously, to remain the same or consistent.

William Wood analyst
#31

Alright, thanks. So then, you've clearly presented data — quite compelling data — from Convergion and Beacon thus far, with Resolve slated for next year. I'm wondering, first, regarding the two trials I just mentioned, how has that shifted things for prescribers and for payers? And then as for Resolve, this appears to be an open-label study without a comparator, whether placebo or, let's say, just denepazole. I'm just curious about precisely what we'll be able to learn from it regarding gains in behavior or cognition, or even tolerability in that trial.

Michael Freeman executive
#32

Thank you. Yes, I'll begin with Resolve; for Resolve, our primary endpoint is tolerability. What matters there is that the trial targets the outpatient with mild to moderate Alzheimer's disease. The data will help physicians treating those patients in an outpatient setting to gauge what tolerability they may observe once Zumbel is started. As a secondary, we have the MPI, the Neurological neuropsychiatric behavioral management by drug; so we will be evaluating that in that trial. If that trial, uh, shows some effect or signal, uh, that would be favorable for the company. Um, and we'll learn more once that trial reads out. On Beacon and Converge, so Beacon has read out, we published the data; we're beginning to see some impact from that. But as you know, it takes multiple calls, uh, touch points with the stakeholders in the segment we call on before that really gains traction; and then with the payers, we've begun some messaging around Beacon; we just released the Converge data and are only now starting discussions with payers on the Converge data set. Notably, the Converge data set is truly significant because it includes more than 6,400 patients, so really large patient numbers. It's a retrospective longitudinal look at what happens when all drugs in the class are used. So very, very important for building modeling that payers examine and value when making a formulary assessment. And it's also really important for assessing some of the cost measures payers evaluate when managing or reviewing a therapeutic class. This class is truly unique in that polypharmacy is rampant in the Alzheimer's category. It's rampant from a side effect management standpoint with GI meds, sleep meds, and other medicines used to try to keep patients on this medication class. And it's also rampant because 90% of patients suffer from neuropsychiatric behaviors; and when they suffer from neuropsychiatric behaviors, if they're on a drug, a drug that isn't ameliorating or lessening those behaviors, they're always put on at least one and often multiple agents to manage those psychiatric behaviors. So when we look at the data showing that Zunvel reduces use of those meds, while patients on other meds actually show an increase, we believe that data will be very persuasive for payers, and it will certainly be just as persuasive to the psychiatrists who consult on treating these behaviors. Got it. That's very helpful. Thank you.

Dave Storms analyst
#33

Thanks for taking my questions. Lauren, I'd like to ask about the prescriber profile. You mentioned that it's now averaging as many as seven prescriptions, up from six in the last quarter. What does that high volume prescriber profile look like? Is it simply a result of their being on the product longer and seeing more patients, or is there a point in time when that begins to plateau? That would be helpful.

Lauren D'Angelo executive
#34

Oh no, absolutely. So it's difficult to give you an exact profile, but what I can say is that some of our earlier adopters and high volume writers, first, they manage a lot of homes, correct? They aren't a single home doctor; they see a lot of patients. So that's one of the top indicators for our highest volume writers. Second, they write a lot of Dinepazil. So obviously when you do a targeting exercise and go after your high volume writers, we've been able to observe that the faster adopters of Zunvale are those Dinepazil writers. Now obviously you'll say, okay, it's the market leader, that makes sense, but there is a specific prescription profile among those physicians who see a number of patients and write a ton of denepazil, because we get a significant number of switches from denepazil. Those are the providers who need a treatment choice for these patients and they've had nothing else, so they use denepazil. So really for us, the high volume profile is obviously a high volume of patients and high denepazil use. And typically we see conversion pretty quickly when we target that specific profile.

Dave Storms analyst
#35

Got it. That's really useful, thanks. Then, Henry, I'd like to ask about the expense run rate. The full-year guidance suggests about 14 million. For the fourth quarter, more or less, I'm just curious how much of that spending you think relates to conversion resolve. I know you aren't giving 2027 guidance yet, but I'm just trying to work backward to what might be coming out in the first half of 2027 and then maybe what gets added, you know, from the p case study, just trying to figure out the puts and takes there.

Henry Du executive
#36

Sorry, could you repeat the last part of the question? I didn't catch that last part.

Dave Storms analyst
#37

I'm just attempting to sort through some of the pluses and minuses we could see for expense early in 2027 — whether that 14 million implied in 4Q is a sensible run rate, or whether a big chunk of that 14 million is tied to a conversion resolve that might fall away in the

Henry Du executive
#38

first half of 2027? That run rate lines up with what we expect for Q4. Regarding costs, they ought to level off somewhat—you might see a slight bump—yet some spending tied to that would remain. Even so, cash flow would mostly go toward commercialization along with routine operating costs.

Dave Storms analyst
#39

Got it. Thanks for that. And if I can just squeeze in one more question, Michael — I know we talked earlier this year about regulatory approvals over in Asia. Maybe just any updates at a high level there, anything we should be watching for in the near term?

Michael Freeman executive
#40

Yes, we filed for approvals in three countries, with products under regulatory review in those three countries, and one of them — the most significant one — being China; we've gone through multiple rounds of questions from the regulatory authorities in China, and their responses, or any further questions they may have on the responses that have been submitted. As for data to tell on any of those, it's in the hands of the regulatory authorities, and we're waiting either for their responses with more questions or for approval of the product.

Michael Freeman executive
#41

Yes, thanks. Thank you, Joe. And thanks to all of you for joining today's call. We think it comes through that our commercial momentum is picking up, that the data on our products keeps getting stronger, and that Zumbel is holding a stronger position against the competition. It feels to us as though the team has kept executing with discipline and focus, so I want to express my appreciation for your being on the call today, for our investors for backing this company, and we will speak with you again next quarter. Thank you.

Operator operator
#42

That wraps up our call for today. You’re welcome to hang up at this point. This real-time transcript is produced automatically, with no person involved and no review afterward. This real-time transcript is produced automatically, with no person involved and no review afterward.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Alpha Cognition Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Alpha Cognition Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.